Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 583

1.

Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis.

Karachaliou N, Chaib I, Cardona AF, Berenguer J, Bracht JWP, Yang J, Cai X, Wang Z, Hu C, Drozdowskyj A, Servat CC, Servat JC, Ito M, Attili I, Aldeguer E, Capitan AG, Rodriguez J, Rojas L, Viteri S, Molina-Vila MA, Ou SI, Okada M, Mok TS, Bivona TG, Ono M, Cui J, Cajal SRY, Cao P, Rosell R.

EBioMedicine. 2018 Feb 5. pii: S2352-3964(18)30050-1. doi: 10.1016/j.ebiom.2018.02.001. [Epub ahead of print]

2.

Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.

Karachaliou N, Gonzalez-Cao M, Crespo G, Drozdowskyj A, Aldeguer E, Gimenez-Capitan A, Teixido C, Molina-Vila MA, Viteri S, De Los Llanos Gil M, Algarra SM, Perez-Ruiz E, Marquez-Rodas I, Rodriguez-Abreu D, Blanco R, Puertolas T, Royo MA, Rosell R.

Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748. doi: 10.1177/1758834017749748. eCollection 2018.

3.

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC).

Moya-Horno I, Viteri S, Karachaliou N, Rosell R.

Ther Adv Med Oncol. 2018 Jan 9;10:1758834017745012. doi: 10.1177/1758834017745012. eCollection 2018. Review.

4.

Possible application of circulating free tumor DNA in non-small cell lung cancer patients.

Karachaliou N, Sosa AE, Molina MA, Centelles Ruiz M, Rosell R.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1364-S1372. doi: 10.21037/jtd.2017.09.59. Review.

5.

An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.

Mayo-de-Las-Casas C, Garzón Ibáñez M, Jordana-Ariza N, García-Peláez B, Balada-Bel A, Villatoro S, Malapelle U, Karachaliou N, Troncone G, Rosell R, Molina-Vila MA.

Expert Rev Mol Diagn. 2018 Jan;18(1):35-45. doi: 10.1080/14737159.2018.1407243. Epub 2017 Nov 26.

PMID:
29172773
6.

Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer.

Codony-Servat J, Cuatrecasas M, Asensio E, Montironi C, Martínez-Cardús A, Marín-Aguilera M, Horndler C, Martínez-Balibrea E, Rubini M, Jares P, Reig O, Victoria I, Gaba L, Martín-Richard M, Alonso V, Escudero P, Fernández-Martos C, Feliu J, Méndez JC, Méndez M, Gallego J, Salud A, Rojo F, Castells A, Prat A, Rosell R, García-Albéniz X, Camps J, Maurel J.

Br J Cancer. 2017 Dec 5;117(12):1777-1786. doi: 10.1038/bjc.2017.279. Epub 2017 Nov 9.

PMID:
29123263
7.

Cross-cultural adaptation and validation of the Spanish version of the Paediatric Throat Disorders Outcome Test (T-14).

Larrosa F, Samara L, Esteller E, Dura MJ, Escamilla Y, Alberti A, Rosell R, Hopkins C.

Clin Otolaryngol. 2017 Nov 9. doi: 10.1111/coa.13029. [Epub ahead of print]

PMID:
29119714
8.

The combination of checkpoint immunotherapy and targeted therapy in cancer.

Karachaliou N, Gonzalez-Cao M, Sosa A, Berenguer J, Bracht JWP, Ito M, Rosell R.

Ann Transl Med. 2017 Oct;5(19):388. doi: 10.21037/atm.2017.06.47. Review.

9.

Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab.

Wills B, Cardona AF, Rojas L, Ruiz-Patiño A, Arrieta O, Reguart N, Carranza H, Vargas C, Otero J, Corrales L, Martín C, Cuello M, Pino LE, Rolfo C, Rosell R, Zatarain-Barrón ZL; Latin-American Consortium for the Investigation of Lung Cancer (CLICaP).

Anticancer Res. 2017 Nov;37(11):6429-6436.

PMID:
29061829
10.

Homage to the titans of Chinese investigation and the race for lung cancer curability.

Rosell R.

J Thorac Dis. 2017 Oct;9(Suppl 11):S1150. doi: 10.21037/jtd.2017.09.145. No abstract available.

11.

Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.

Wu YL, Cheng Y, Zhou X, Lee KH, Nakagawa K, Niho S, Tsuji F, Linke R, Rosell R, Corral J, Migliorino MR, Pluzanski A, Sbar EI, Wang T, White JL, Nadanaciva S, Sandin R, Mok TS.

Lancet Oncol. 2017 Nov;18(11):1454-1466. doi: 10.1016/S1470-2045(17)30608-3. Epub 2017 Sep 25.

PMID:
28958502
12.

First report of the novel atypical porcine pestivirus in Spain and a retrospective study.

Muñoz-González S, Canturri A, Pérez-Simó M, Bohórquez JA, Rosell R, Cabezón O, Segalés J, Domingo M, Ganges L.

Transbound Emerg Dis. 2017 Dec;64(6):1645-1649. doi: 10.1111/tbed.12699. Epub 2017 Sep 21.

PMID:
28941140
13.

BRAFV600E and BRAF-inactivating mutations in NSCLC.

Rosell R, Karachaliou N.

Lancet Oncol. 2017 Oct;18(10):1286-1287. doi: 10.1016/S1470-2045(17)30678-2. Epub 2017 Sep 11. No abstract available.

PMID:
28919012
14.

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions.

Mayo-de-Las-Casas C, Jordana-Ariza N, Garzón-Ibañez M, Balada-Bel A, Bertrán-Alamillo J, Viteri-Ramírez S, Reguart N, Muñoz-Quintana MA, Lianes-Barragan P, Camps C, Jantús E, Remon-Massip J, Calabuig S, Aguiar D, Gil ML, Viñolas N, Santos-Rodríguez AK, Majem M, García-Peláez B, Villatoro S, Pérez-Rosado A, Monasterio JC, Ovalle E, Catalán MJ, Campos R, Morales-Espinosa D, Martínez-Bueno A, González-Cao M, González X, Moya-Horno I, Sosa AE, Karachaliou N, Rosell R, Molina-Vila MA.

Ann Oncol. 2017 Sep 1;28(9):2248-2255. doi: 10.1093/annonc/mdx288.

PMID:
28911086
15.

IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.

Etxaniz O, Carrato C, de Aguirre I, Queralt C, Muñoz A, Ramirez JL, Rosell R, Villà S, Diaz R, Estival A, Teixidor P, Indacochea A, Ahjal S, Vilà L, Balañá C.

J Neurooncol. 2017 Nov;135(2):273-284. doi: 10.1007/s11060-017-2570-1. Epub 2017 Sep 7.

PMID:
28884377
16.

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.

Jacobsen K, Bertran-Alamillo J, Molina MA, Teixidó C, Karachaliou N, Pedersen MH, Castellví J, Garzón M, Codony-Servat C, Codony-Servat J, Giménez-Capitán A, Drozdowskyj A, Viteri S, Larsen MR, Lassen U, Felip E, Bivona TG, Ditzel HJ, Rosell R.

Nat Commun. 2017 Sep 4;8(1):410. doi: 10.1038/s41467-017-00450-6.

17.

Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.

Santarpia M, Liguori A, Karachaliou N, Gonzalez-Cao M, Daffinà MG, D'Aveni A, Marabello G, Altavilla G, Rosell R.

Lung Cancer (Auckl). 2017 Aug 18;8:109-125. doi: 10.2147/LCTT.S119644. eCollection 2017. Review.

18.

Tracking MET de-addiction in lung cancer: A road towards the oncogenic target.

Pilotto S, Carbognin L, Karachaliou N, Ma PC, Rosell R, Tortora G, Bria E.

Cancer Treat Rev. 2017 Nov;60:1-11. doi: 10.1016/j.ctrv.2017.08.002. Epub 2017 Aug 20. Review.

PMID:
28843992
19.

Monitoring of Schmallenberg virus in Spanish wild artiodactyls, 2006-2015.

García-Bocanegra I, Cano-Terriza D, Vidal G, Rosell R, Paniagua J, Jiménez-Ruiz S, Expósito C, Rivero-Juarez A, Arenas A, Pujols J.

PLoS One. 2017 Aug 16;12(8):e0182212. doi: 10.1371/journal.pone.0182212. eCollection 2017.

20.

Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets.

Best MG, Sol N, In 't Veld SGJG, Vancura A, Muller M, Niemeijer AN, Fejes AV, Tjon Kon Fat LA, Huis In 't Veld AE, Leurs C, Le Large TY, Meijer LL, Kooi IE, Rustenburg F, Schellen P, Verschueren H, Post E, Wedekind LE, Bracht J, Esenkbrink M, Wils L, Favaro F, Schoonhoven JD, Tannous J, Meijers-Heijboer H, Kazemier G, Giovannetti E, Reijneveld JC, Idema S, Killestein J, Heger M, de Jager SC, Urbanus RT, Hoefer IE, Pasterkamp G, Mannhalter C, Gomez-Arroyo J, Bogaard HJ, Noske DP, Vandertop WP, van den Broek D, Ylstra B, Nilsson RJA, Wesseling P, Karachaliou N, Rosell R, Lee-Lewandrowski E, Lewandrowski KB, Tannous BA, de Langen AJ, Smit EF, van den Heuvel MM, Wurdinger T.

Cancer Cell. 2017 Aug 14;32(2):238-252.e9. doi: 10.1016/j.ccell.2017.07.004.

21.

Corrigendum to "Characterization of the efficiency and uncertainty of skimmed milk flocculation for the simultaneous concentration and quantification of water-borne viruses, bacteria and protozoa" [J. Microbiol. Methods 134 (2017) 46-53].

Gonzales-Gustavson E, Cárdenas-Youngs Y, Calvo M, da Silva MFM, Hundesa A, Amorós I, Moreno Y, Moreno-Mesonero L, Rosell R, Ganges L, Araujo R, Girones R.

J Microbiol Methods. 2017 Nov;142:96. doi: 10.1016/j.mimet.2017.07.016. Epub 2017 Aug 9. No abstract available.

22.

African swine fever virus infection in Classical swine fever subclinically infected wild boars.

Cabezón O, Muñoz-González S, Colom-Cadena A, Pérez-Simó M, Rosell R, Lavín S, Marco I, Fraile L, de la Riva PM, Rodríguez F, Domínguez J, Ganges L.

BMC Vet Res. 2017 Aug 1;13(1):227. doi: 10.1186/s12917-017-1150-0.

23.

Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, development and place in therapy.

Santarpia M, Daffinà MG, D'Aveni A, Marabello G, Liguori A, Giovannetti E, Karachaliou N, Gonzalez Cao M, Rosell R, Altavilla G.

Drug Des Devel Ther. 2017 Jul 5;11:2047-2063. doi: 10.2147/DDDT.S113500. eCollection 2017. Review.

24.

Brain metastases in patients with EGFR-mutant non-small-cell lung cancer.

Rosell R, Karachaliou N.

Lancet Respir Med. 2017 Sep;5(9):669-671. doi: 10.1016/S2213-2600(17)30265-5. Epub 2017 Jul 19. No abstract available.

PMID:
28734820
25.

AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patients.

Bottai G, Raschioni C, Székely B, Di Tommaso L, Szász AM, Losurdo A, Győrffy B, Ács B, Torrisi R, Karachaliou N, Tőkés T, Caruso M, Kulka J, Roncalli M, Santoro A, Mantovani A, Rosell R, Reis-Filho JS, Santarpia L.

NPJ Breast Cancer. 2016 Nov 2;2:16033. doi: 10.1038/npjbcancer.2016.33. eCollection 2016.

26.

A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.

Moran T, Palmero R, Provencio M, Insa A, Majem M, Reguart N, Bosch-Barrera J, Isla D, Costa EC, Lee C, Puig M, Kraemer S, Schnell D, Rosell R.

Lung Cancer. 2017 Jun;108:154-160. doi: 10.1016/j.lungcan.2017.03.009. Epub 2017 Mar 22.

PMID:
28625629
27.

YB-1 regulates tumor growth by promoting MACC1/c-Met pathway in human lung adenocarcinoma.

Guo T, Zhao S, Wang P, Xue X, Zhang Y, Yang M, Li N, Li Z, Xu L, Jiang L, Zhao L, Ma PC, Rosell R, Li J, Gu C.

Oncotarget. 2017 Jul 18;8(29):48110-48125. doi: 10.18632/oncotarget.18262.

28.

Acquired Resistance to Erlotinib in EGFR Mutation-Positive Lung Adenocarcinoma among Hispanics (CLICaP).

Cardona AF, Arrieta O, Zapata MI, Rojas L, Wills B, Reguart N, Karachaliou N, Carranza H, Vargas C, Otero J, Archila P, Martín C, Corrales L, Cuello M, Ortiz C, Pino LE, Rosell R, Zatarain-Barrón ZL; CLICaP.

Target Oncol. 2017 Aug;12(4):513-523. doi: 10.1007/s11523-017-0497-2.

PMID:
28620690
29.

Neutrophils dominate the immune landscape of non-small cell lung cancer.

Teixidó C, Rosell R.

J Thorac Dis. 2017 May;9(5):E468-E469. doi: 10.21037/jtd.2017.04.55. No abstract available.

30.

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Peters S, Camidge DR, Shaw AT, Gadgeel S, Ahn JS, Kim DW, Ou SI, Pérol M, Dziadziuszko R, Rosell R, Zeaiter A, Mitry E, Golding S, Balas B, Noe J, Morcos PN, Mok T; ALEX Trial Investigators.

N Engl J Med. 2017 Aug 31;377(9):829-838. doi: 10.1056/NEJMoa1704795. Epub 2017 Jun 6.

PMID:
28586279
31.

A bivalent dendrimeric peptide bearing a T-cell epitope from foot-and-mouth disease virus protein 3A improves humoral response against classical swine fever virus.

Bohórquez JA, Defaus S, Muñoz-González S, Perez-Simó M, Rosell R, Fraile L, Sobrino F, Andreu D, Ganges L.

Virus Res. 2017 Jun 15;238:8-12. doi: 10.1016/j.virusres.2017.05.020. Epub 2017 May 30.

PMID:
28571760
32.

Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC).

Codony-Servat C, Codony-Servat J, Karachaliou N, Molina MA, Chaib I, Ramirez JL, de Los Llanos Gil M, Solca F, Bivona TG, Rosell R.

Oncotarget. 2017 Jul 18;8(29):47305-47316. doi: 10.18632/oncotarget.17625.

33.

Consistency and reproducibility of next-generation sequencing and other multigene mutational assays: A worldwide ring trial study on quantitative cytological molecular reference specimens.

Malapelle U, Mayo-de-Las-Casas C, Molina-Vila MA, Rosell R, Savic S, Bihl M, Bubendorf L, Salto-Tellez M, de Biase D, Tallini G, Hwang DH, Sholl LM, Luthra R, Weynand B, Vander Borght S, Missiaglia E, Bongiovanni M, Stieber D, Vielh P, Schmitt F, Rappa A, Barberis M, Pepe F, Pisapia P, Serra N, Vigliar E, Bellevicine C, Fassan M, Rugge M, de Andrea CE, Lozano MD, Basolo F, Fontanini G, Nikiforov YE, Kamel-Reid S, da Cunha Santos G, Nikiforova MN, Roy-Chowdhuri S, Troncone G; Molecular Cytopathology Meeting Group.

Cancer Cytopathol. 2017 Aug;125(8):615-626. doi: 10.1002/cncy.21868. Epub 2017 May 5.

PMID:
28475299
34.

Second-line therapy of squamous non-small cell lung cancer: an evolving landscape.

Lazzari C, Karachaliou N, Gregorc V, Bulotta A, Gonzalez-Cao M, Verlicchi A, Altavilla G, Rosell R, Santarpia M.

Expert Rev Respir Med. 2017 Jun;11(6):469-479. doi: 10.1080/17476348.2017.1326822. Epub 2017 May 15. Review.

PMID:
28467720
35.

Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.

Karachaliou N, Santarpia M, Gonzalez Cao M, Teixido C, Sosa AE, Berenguer J, Rodriguez Capote A, Altavilla G, Rosell R.

Expert Opin Investig Drugs. 2017 Jun;26(6):713-722. doi: 10.1080/13543784.2017.1324572. Epub 2017 May 18. Review.

PMID:
28463570
36.

High BIM mRNA levels are associated with longer survival in advanced gastric cancer.

Wu N, Huang Y, Zou Z, Gimenez-Capitan A, Yu L, Hu W, Zhu L, Sun X, Sanchez JJ, Guan W, Liu B, Rosell R, Wei J.

Oncol Lett. 2017 Mar;13(3):1826-1834. doi: 10.3892/ol.2017.5660. Epub 2017 Feb 1.

37.

Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.

Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A.

J Clin Oncol. 2017 May 1;35(13):1403-1410. doi: 10.1200/JCO.2016.70.9352. Epub 2017 Mar 13.

38.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix SP, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames DS, Molina-Vila MA, Stahel RA; BELIEF collaborative group.

Lancet Respir Med. 2017 May;5(5):435-444. doi: 10.1016/S2213-2600(17)30129-7. Epub 2017 Apr 10.

PMID:
28408243
39.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC.

Chaib I, Karachaliou N, Pilotto S, Codony Servat J, Cai X, Li X, Drozdowskyj A, Servat CC, Yang J, Hu C, Cardona AF, Vivanco GL, Vergnenegre A, Sanchez JM, Provencio M, de Marinis F, Passaro A, Carcereny E, Reguart N, Campelo CG, Teixido C, Sperduti I, Rodriguez S, Lazzari C, Verlicchi A, de Aguirre I, Queralt C, Wei J, Estrada R, Puig de la Bellacasa R, Ramirez JL, Jacobson K, Ditzel HJ, Santarpia M, Viteri S, Molina MA, Zhou C, Cao P, Ma PC, Bivona TG, Rosell R.

J Natl Cancer Inst. 2017 Sep 1;109(9). doi: 10.1093/jnci/djx014.

40.

Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.

Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.

J Natl Cancer Inst. 2017 Jun 1;109(6). doi: 10.1093/jnci/djw279. Review.

PMID:
28376144
41.

Novel poly-uridine insertion in the 3'UTR and E2 amino acid substitutions in a low virulent classical swine fever virus.

Coronado L, Liniger M, Muñoz-González S, Postel A, Pérez LJ, Pérez-Simó M, Perera CL, Frías-Lepoureau MT, Rosell R, Grundhoff A, Indenbirken D, Alawi M, Fischer N, Becher P, Ruggli N, Ganges L.

Vet Microbiol. 2017 Mar;201:103-112. doi: 10.1016/j.vetmic.2017.01.013. Epub 2017 Jan 17.

PMID:
28284595
42.

Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.

Malapelle U, Mayo de-Las-Casas C, Rocco D, Garzon M, Pisapia P, Jordana-Ariza N, Russo M, Sgariglia R, De Luca C, Pepe F, Martinez-Bueno A, Morales-Espinosa D, González-Cao M, Karachaliou N, Viteri Ramirez S, Bellevicine C, Molina-Vila MA, Rosell R, Troncone G.

Br J Cancer. 2017 Mar 14;116(6):802-810. doi: 10.1038/bjc.2017.8. Epub 2017 Feb 7.

PMID:
28170370
43.

Human endogenous retroviruses and cancer.

Gonzalez-Cao M, Iduma P, Karachaliou N, Santarpia M, Blanco J, Rosell R.

Cancer Biol Med. 2016 Dec;13(4):483-488. doi: 10.20892/j.issn.2095-3941.2016.0080.

44.

Beyond platinum treatment for NSCLC: what does the future hold?

Santarpia M, Karachaliou N, Rosell R.

Expert Rev Anticancer Ther. 2017 Apr;17(4):293-295. doi: 10.1080/14737140.2017.1288103. Epub 2017 Feb 8. No abstract available.

PMID:
28129003
45.

Pharmacological management of relapsed/refractory NSCLC with chemical drugs.

Karachaliou N, Sosa AE, Barron FB, Gonzalez Cao M, Santarpia M, Rosell R.

Expert Opin Pharmacother. 2017 Feb;18(3):295-304. doi: 10.1080/14656566.2017.1285284. Epub 2017 Jan 29. Review.

PMID:
28103738
46.

Characterization of the efficiency and uncertainty of skimmed milk flocculation for the simultaneous concentration and quantification of water-borne viruses, bacteria and protozoa.

Gonzales-Gustavson E, Cárdenas-Youngs Y, Calvo M, da Silva MF, Hundesa A, Amorós I, Moreno Y, Moreno-Mesonero L, Rosell R, Ganges L, Araujo R, Girones R.

J Microbiol Methods. 2017 Mar;134:46-53. doi: 10.1016/j.mimet.2017.01.006. Epub 2017 Jan 16.

47.

Identification of ALK, ROS1, and RET Fusions by a Multiplexed mRNA-Based Assay in Formalin-Fixed, Paraffin-Embedded Samples from Advanced Non-Small-Cell Lung Cancer Patients.

Reguart N, Teixidó C, Giménez-Capitán A, Paré L, Galván P, Viteri S, Rodríguez S, Peg V, Aldeguer E, Viñolas N, Remon J, Karachaliou N, Conde E, Lopez-Rios F, Nadal E, Merkelbach-Bruse S, Büttner R, Rosell R, Molina-Vila MA, Prat A.

Clin Chem. 2017 Mar;63(3):751-760. doi: 10.1373/clinchem.2016.265314. Epub 2017 Jan 10.

PMID:
28073897
48.

Liquid Biopsy in Non-Small Cell Lung Cancer.

Molina-Vila MA, Mayo-de-Las-Casas C, Giménez-Capitán A, Jordana-Ariza N, Garzón M, Balada A, Villatoro S, Teixidó C, García-Peláez B, Aguado C, Catalán MJ, Campos R, Pérez-Rosado A, Bertran-Alamillo J, Martínez-Bueno A, Gil MD, González-Cao M, González X, Morales-Espinosa D, Viteri S, Karachaliou N, Rosell R.

Front Med (Lausanne). 2016 Dec 23;3:69. doi: 10.3389/fmed.2016.00069. eCollection 2016. Review.

49.

Spatial and Temporal Phylogeny of Border Disease Virus in Pyrenean Chamois (Rupicapra p. pyrenaica).

Luzzago C, Ebranati E, Cabezón O, Fernández-Sirera L, Lavín S, Rosell R, Veo C, Rossi L, Cavallero S, Lanfranchi P, Marco I, Zehender G.

PLoS One. 2016 Dec 29;11(12):e0168232. doi: 10.1371/journal.pone.0168232. eCollection 2016.

50.

HER3 as a Therapeutic Target in Cancer.

Karachaliou N, Lazzari C, Verlicchi A, Sosa AE, Rosell R.

BioDrugs. 2017 Feb;31(1):63-73. doi: 10.1007/s40259-016-0205-2. Review.

PMID:
28000159

Supplemental Content

Loading ...
Support Center